Compare AEF & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AEF | XOMA |
|---|---|---|
| Founded | 1989 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 315.9M | 308.6M |
| IPO Year | N/A | N/A |
| Metric | AEF | XOMA |
|---|---|---|
| Price | $7.45 | $28.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $60.60 |
| AVG Volume (30 Days) | ★ 190.4K | 112.9K |
| Earning Date | 01-01-0001 | 03-18-2026 |
| Dividend Yield | ★ 7.13% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.57 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $24.95 |
| Revenue Next Year | N/A | $6.20 |
| P/E Ratio | ★ $13.46 | $29.64 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.43 | $18.40 |
| 52 Week High | $8.93 | $39.92 |
| Indicator | AEF | XOMA |
|---|---|---|
| Relative Strength Index (RSI) | 37.83 | 62.75 |
| Support Level | $6.10 | $23.92 |
| Resistance Level | $8.09 | $35.17 |
| Average True Range (ATR) | 0.25 | 1.55 |
| MACD | -0.07 | 0.23 |
| Stochastic Oscillator | 2.73 | 69.10 |
ABERDEEN EMERGING MARKETS EQUITY INCOME FUND, INC. is a closed-end investment company. The Fund's investment objective is to seek to provide both current income and long-term capital appreciation. The Fund invests in a range of sectors, including financials, consumer staples, utilities, consumer discretionary, materials, energy, information technology, private equity, communication services, healthcare, real estate, and industrials.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.